Dividend and Profit Distribution - The company plans to distribute a cash dividend of 7.5 RMB per 10 shares (including tax) to all shareholders for the first half of 2024[2]. - The company’s total distributable profit is 688,552,142.04 RMB, with cash dividends fully accounted for in the profit distribution[110]. - The company approved a cash dividend of 10.00 CNY per 10 shares (including tax) based on the total share capital after deducting repurchased shares[134]. - The company distributed cash dividends of 10.00 CNY per 10 shares to all shareholders during the reporting period[117]. Financial Performance - The company's operating revenue for the current reporting period is ¥2,629,136,482.55, representing a year-on-year increase of 9.58% compared to ¥2,399,390,445.62 in the same period last year[12]. - The net profit attributable to shareholders of the listed company is ¥373,176,957.09, which is a 4.90% increase from ¥355,736,663.75 in the previous year[12]. - The net cash flow from operating activities has decreased significantly by 79.95%, amounting to ¥222,632,168.41 compared to ¥1,110,292,947.91 in the previous year[12]. - The basic earnings per share for the current period is ¥0.9450, reflecting a 6.26% increase from ¥0.8893 in the same period last year[12]. - The total comprehensive income for the first half of 2024 was ¥375,597,035.71, compared to ¥357,746,026.14 in the same period last year, reflecting an increase of 5.0%[160]. Risk Management and Corporate Governance - The company emphasizes the importance of risk awareness in its future operational plans, as outlined in the management discussion section[2]. - The company has a comprehensive risk management strategy in place, detailing potential risks and corresponding countermeasures[2]. - The report includes a commitment to maintaining high standards of corporate governance and compliance with regulatory requirements[2]. - The financial report is guaranteed to be true, accurate, and complete by the company's responsible personnel, including the CEO and accounting head[2]. Market and Product Development - The company is focused on enhancing its product development and market expansion strategies to drive future growth[2]. - The company continues to focus on the development of high-end health sleep products, with mattresses being the core product, emphasizing innovation in design and materials[17]. - The company has established two digital intelligent manufacturing bases in South China and East China, supporting a diversified and multi-channel sales network across the country[17]. - The company is collaborating with authoritative institutions to integrate ergonomics and sleep environment studies into its AI smart products, enhancing its product matrix[17]. - The company has introduced a new AI mattress that can adjust in real-time based on individual conditions, showcasing its commitment to technological innovation[18]. Sales and Distribution Channels - The e-commerce channel's official flagship store model accounted for about 94% of the revenue generated from e-commerce during the reporting period[28]. - The company focuses on a multi-channel sales model, including distribution, e-commerce, direct supply, and direct sales[26]. - The company’s direct supply channel primarily serves B-end clients, including major hotel groups and banks[29]. - The company employs a "make-to-order" production model, with a production cycle of approximately 9-15 days from order receipt to shipment[25]. Research and Development - The company has established a research and development innovation center to enhance its product and technology development capabilities[31]. - The company has maintained the top sales position in China's high-end mattress market for six consecutive years from 2018 to 2023, according to research by Shangpu Consulting[56]. - The company has been awarded the "National Furniture Standardization Advanced Collective" title for several consecutive years, highlighting its commitment to quality standards[57]. - The company has a total of 3,507 valid intellectual property rights, including 141 domestic invention patents and 1,671 trademarks, reflecting its commitment to innovation and protection of technology[67]. Corporate Social Responsibility - The company has maintained a strong commitment to corporate social responsibility, actively participating in various community support initiatives[121]. - The company donated beddings worth 512,000 CNY to several schools during the reporting period[121]. - The company has cumulatively recruited 879 employees from impoverished areas to support rural revitalization efforts[122]. - The company has implemented a clean production certification and invested approximately 1.1 million CNY to upgrade its dust removal system[121]. Shareholder Structure and Management - The total number of common shareholders at the end of the reporting period was 11,264[142]. - The company has not made any changes to its board of directors, supervisors, or senior management during the reporting period[109]. - The company has not initiated any stock incentive plans during the reporting period[111]. - The company has engaged in ongoing management reforms and innovations to stimulate the vitality of its marketing organization[106]. Investment and Financial Management - The company reported a total cash inflow from investment activities of CNY 2,298,404,899.95, compared to CNY 701,350,136.99 in the previous year, showing a substantial increase[164]. - The company has entrusted financial management with a total amount of 155,000, including 110,000 in bank financial products and 20,000 in raised funds[130]. - The company has not made any significant asset or equity sales during the reporting period, maintaining its asset base[94]. - The company has not experienced any major changes in project feasibility during the reporting period, indicating stability in its operations[93].

证券代码：001323 证券简称：慕思股份 公告编号：2024-058 慕思健康睡眠股份有限公司 第二届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 慕思健康睡眠股份有限公司（以下简称"公司"）第二届董事会第八次会议 由董事长王炳坤先生召集，会议通知于 2024 年 8 月 17 日以邮件、微信、电话的 方式送达全体董事，并于 2024 年 8 月 27 日上午 10:00 以现场及通讯的方式在公 司会议室召开。本次会议应出席董事 7 人，实际出席董事 7 人（其中独立董事李 飞德先生以通讯方式出席会议）。会议由董事长王炳坤先生主持，公司监事及高 级管理人员列席了会议。本次会议的出席人数、召集、召开程序和议事内容均符 合《中华人民共和国公司法》等相关法律法规和《公司章程》的有关规定，会议 形成的决议合法有效。 二、董事会会议审议情况 经与会各位董事认真审议，会议形成了如下决议： （一）审议通过《关于公司<2024 年半年度报告>及其摘要的议案》 根据《公司法》《上市公司信息披露管理办法》《深圳证券交易所上市公 ...

| 编制单位：慕思健康睡眠股份有限公司 | | | | | | | | | | 单位：万元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 占用方与上市公司的关 | 上市公司核 | 2024年期初往来 | 2024年1-6月往来 | 2024年1-6月往来 | 2024年1-6月偿还 | 2024年6月30日往 | | | | 非经营性资金占用 | 资金占用方名称 | 联关系 | 算的会计 | 资金余额 | 累计发生金额 | 资金的利息(如 | 累计发生金额 | 来资金余额 | 占用形成原因 | 占用性质 | | | | | 科目 | | （不含利息） | 有) | | | | | | 控股股东、实际控制 | | | | - | | - - | - | - | | | | 人及其附属企业 | | | | | | | | | | | | 前控股股东、实际控 | | | | - | | - - | - | - | | | | 制人及其附属企业 | | | | | | | | | | | | 其他关联方及附属企 ...

证券代码：001323 证券简称：慕思股份 公告编号：2024-059 慕思健康睡眠股份有限公司 第二届监事会第六次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 慕思健康睡眠股份有限公司（以下简称"公司"）第二届监事会第六次会议 由监事会主席罗振彪先生召集，会议通知于 2024 年 8 月 17 日以邮件、微信、电 话的方式送达全体监事，并于 2024 年 8 月 27 日上午 11:00 以现场及通讯的方式 在公司会议室召开。本次会议应出席监事 3 人，实际出席监事 3 人（其中职工代 表监事汪玉芳女士以通讯方式出席会议），会议由监事会主席罗振彪先生主持， 公司董事会秘书赵元贵先生列席本次会议。本次会议的出席人数、召集、召开程 序和议事内容均符合《中华人民共和国公司法》等相关法律法规以及《公司章程》 等的相关规定，会议形成的决议合法有效。 二、监事会会议审议情况 经各位监事认真审议，会议形成了如下决议： （一）审议通过《关于公司<2024 年半年度报告>及其摘要的议案》 经审核，监事会认为：董事会编制和审核公司《202 ...

证券代码：001323 证券简称：慕思股份 公告编号：2024-064 慕思健康睡眠股份有限公司 3、会议召开的合法、合规性：公司第二届董事会第八次会议审议通过了《关 于提请召开 2024 年第二次临时股东大会的议案》。本次股东大会会议召集、召 开符合有关法律、行政法规、部门规章、规范性文件以及公司章程的规定。 关于召开公司 2024 年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要提示 股东大会召开日期：2024 年 9 月 13 日 本次股东大会采用的网络投票系统：深圳证券交易所股东大会网络投票 系统 根据《公司法》及《公司章程》的有关规定，经慕思健康睡眠股份有限公司 （以下简称"公司"或"本公司"）第二届董事会第八次会议审议通过，决定于 2024 年 9 月 13 日（星期五）下午 14:50 召开公司 2024 年第二次临时股东大会， 现将本次股东大会的有关事项通知如下： 一、召开会议的基本情况 1．会议届次：2024 年第二次临时股东大会 2、会议召集人：公司董事会 4、会议召开的日期和时间： （1）现场会议时间：20 ...

为积极回报股东，与股东分享公司发展的经营成果，结合公司的实际经营情 况，公司拟以 2024 年半年度权益分派实施时股权登记日的总股本扣除公司回购 专户上的股份后的股本为基数（暂以截至本公告披露日公司总股本 400,010,000 股扣除公司回购专户上已回购股份 5,750,289 股后的股本 394,259,711 股测算）向 单位:元 项目 合并报表 母公司报表 期初经审计未分配利润 1,314,859,375.84 822,645,557.15 减：利润分配 398,771,966.00 398,771,966.00 加：本期净利润 373,176,957.09 264,678,550.89 减：提取盈余公积 - - 期末未分配利润 1,289,264,366.93 688,552,142.04 证券代码：001323 证券简称：慕思股份 公告编号：2024-063 慕思健康睡眠股份有限公司 关于 2024 年半年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 慕思健康睡眠股份有限公司（以下简称"公司"）于 2024 年 8 月 27 ...

慕思健康睡眠股份有限公司 证券代码：001323 证券简称：慕思股份 公告编号：2024-062 经中国证券监督管理委员会证监许可[2022]831 号文核准，并经深圳证券交 易所同意，本公司由主承销商招商证券股份有限公司通过深圳证券交易所系统采 用网下向符合条件的投资者询价配售与网上向持有深圳市场非限售 A 股和非限 售存托凭证市值的社会公众投资者定价发行相结合的方式，向社会公众公开发行 人民币普通股（A 股）4,001 万股，发行价为每股人民币 38.93 元。截至 2022 年 6 月 20 日，本公司共募集资金 155,758.93 万元，扣除发行费用 8,044.55 万元 后，本公司本次募集资金净额为人民币 147,714.38 万元。 （二）募集资金使用和结余情况 1、以前年度已使用金额 截至 2023 年 12 月 31 日，募集资金投资项目累计投入 83,167.22 万元，尚未 使用的金额为 69,052.59 万元（其中募集资金 64,547.17 万元，专户存储累计利息 扣除手续费 4,505.42 万元）。 2、本年度使用金额及当前余额 2024 年半年度，本公司募集资金使用情况为： ...

Investment Rating - The report maintains an "Outperform" rating for the company [1] Core Insights - The company is positioned as a leading player in the furniture industry, with expected revenue growth driven by the expansion of its consumer base and product categories, alongside significant improvements in profitability through cost reduction and efficiency enhancement [3][4][5] Revenue Growth Potential - The company is benefiting from a continuous expansion of its consumer base, particularly targeting high-end and younger demographics. The core price range for its main brand mattresses is approximately 3,200 to 9,100 yuan, indicating a high-end positioning with substantial growth potential [4][21] - The mattress market in China was valued at 70.8 billion yuan in 2020, with a compound annual growth rate (CAGR) of 7.9% from 2015 to 2020, driven by increasing penetration rates and a growing focus on sleep-related products [4][21] - The company has diversified its product offerings, including mattresses, bed frames, sofas, and customized furniture, which is expected to enhance average transaction values through bundled sales [4][5] Profitability Improvement - The company's gross margin has shown a significant recovery, reaching 52.2% in Q2 2023, up 5.3 percentage points year-on-year, attributed to a reduction in direct supply business and a favorable shift in product mix [4][5] - The company is expected to benefit from economies of scale, with fixed marketing costs being spread over a larger revenue base, similar to trends observed in the real estate sector [4][5] Financial Projections - The company is projected to achieve net profits of 885 million yuan, 972 million yuan, and 1.097 billion yuan for the years 2024, 2025, and 2026, respectively, reflecting year-on-year growth rates of 10.4%, 9.7%, and 12.9% [5][6] - The current closing price corresponds to a price-to-earnings (PE) ratio of 13 and 12 times for 2024 and 2025, respectively, with a target valuation range of 39.84 to 42.06 yuan based on comparable company analysis [5] Market Positioning - The company has established a comprehensive brand matrix that includes high-end and trendy products, catering to the evolving preferences of younger consumers. This includes the introduction of new brands and series aimed at capturing the growing market share among younger demographics [4][27][28] - The company’s e-commerce channel has seen rapid growth, achieving revenue of 1.03 billion yuan in 2023, a year-on-year increase of 29.2%, with a compound annual growth rate of 25.5% from 2018 to 2023 [31][32]

证券代码：001323 证券简称：慕思股份 公告编号：2024-056 慕思健康睡眠股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 二、其他说明 公司回购股份的时间、回购股份数量、回购股份价格及集中竞价交易的委托 时段符合《回购指引》第十七条、十八条的相关规定，具体说明如下： 1、公司未在下列期间回购公司股份： （1）自可能对本公司证券及其衍生品种交易价格产生重大影响的重大事项 发生之日或者在决策过程中，至依法披露之日内； （2）中国证监会和深圳证券交易所规定的其他情形。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 慕思健康睡眠股份有限公司（以下简称"公司"）公司于 2024 年 7 月 2 日 召开第二届董事会第七次会议和第二届监事会第五次会议，并于 2024 年 7 月 19 日召开 2024 年第一次临时股东大会，审议通过了《关于以集中竞价交易方式回 购公司股份方案的议案》，同意公司使用自有资金通过深圳证券交易所交易系统 以集中竞价交易方式回购部分公司股份，本次回购股份将全部用于注销以减少注 册资本。本次回购股份的种类为公司发行的 A 股 ...

证券代码：001323 证券简称：慕思股份 公告编号：2024-055 慕思健康睡眠股份有限公司 关于以集中竞价交易方式首次回购公司股份的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 慕思健康睡眠股份有限公司（以下简称"公司"）公司于 2024 年 7 月 2 日 召开第二届董事会第七次会议和第二届监事会第五次会议，并于 2024 年 7 月 19 日召开 2024 年第一次临时股东大会，审议通过了《关于以集中竞价交易方式回 购公司股份方案的议案》，同意公司使用自有资金通过深圳证券交易所交易系统 以集中竞价交易方式回购部分公司股份，本次回购股份将全部用于注销以减少注 册资本。本次回购股份的种类为公司发行的 A 股社会公众股份，回购资金总额 不低于人民币 12,000 万元（含），不超过人民币 24,000 万元（含），回购价格 不超过人民币 39 元/股（含）；按回购金额上限人民币 24,000 万元、回购价格上 限 39 元/股测算，回购股份数量约为 6,153,846 股，占公司目前总股本的 1.54%； 按回购金额下限人民币 12,000 万元、 ...